P. Castrogiovanni, S. Iapichino, F. Pieraccini - Vol. 6, Settembre 2000, num.3
Testo Immagini Bibliografia Summary Riassunto Indice
Neurolettici tradizionali e nuovi antipsicotici
nella relazione terapeutica
Typical and atypical antipsychotic drugs in therapist-patient relationship
1 Shriqui CL, Nasrallah HA.
Contemporary Issues in the Treatment of Schizophrenia.
Washington: American Psychiatric Press 1997.
2 Casey DE.
Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia.
Schizophr Res 1991;4:109-20.
3 Angst J, Stassen HH, Woggon B.
Effect of neuroleptics on positive and negative symptoms and the deficit
state.
Psychopharmacology (Berl)1989;99:S41-S46.
4 Meltzer HY, Matsubara S, Lee JC.
Classification of typical and atypical antipsychotic drugs on the basis
of dopamine D1, D2 and serotonin-2 pKi values.
J Pharmacol Exp Ther 1989;251:238-51.
5 Claus A, Bollen J, De Cuyper H.
Risperidone versus haloperidol in the treatment of chronic schizophrenic
inpatients: a multi-center, double-blind comparative study.
Acta Psychiatr Scand 1992;85:295-305.
6 Carpenter WT, Heinrichs DW, Hanlon TE.
Interpersonal and pharmacologic treatment in schizophrenia: a comparative
study of new approaches.
Psychopharmacol Bull 1986;22:845-59.
7 Borison RL, Rathiraja AP, Bruce I.
Risperidone clinical safety and efficacy in schizophrenia.
Psychopharmacol Bull 1992;28:213-8.
8 Barnes TRE, Liddle PF, Curson DA.
Negative symptoms, tardive dyskinesia, and depression in chronic schizophrenia.
Br J Psychiatry 1989;25:826-34.
9 Pearce JMS.
The placebo enigma.
Q J Med 1995;88:215-20.
10 Besson A, Privat AM, Aschalier A, Fralie J.
Effect of morphine, naloxone and their interaction in the learned-helplessness
paradigm in rats.
Psychopharmacology (Berl) 1996;123:71-8.
11 Gilberg C, Coleman M.
The biology of the autistic syndromes.
New York: Cambridge University Press 1992.
12 Kauffman B, Dobler-Mikola A, Zimmer-Hofler D.
The significance of self-concept and coping for long-term rehabilitation
of heroin addicts.
Sucht 1993;39:244-54.
13 Davis KL, Kahn RS, Ko G.
Dopamine in schizophrenia: a review and reconceptualization.
Am J Psychiatry 1991;148:1474-86.
14 Orsulack PJ.
The decade of the brain: recent developments in the neurochemistry of
depression, mania and other mood disorders.
Clin Chem 1994;40:271-2.
15 Stein MB, Liebowitz MR, Lydiard B, Pitts CD, Bushnell W, Gergel I.
Trattamento con paroxetina della fobia sociale generalizzata (trad.it.).
JAMA 1998;280:708-13.
16 Perani D, Colombo C, Bressi S, Bonfanti A, Gressi F, Scarone S, et al.
FDG-PET study in obsessive-compulsive disorder. A clinical /metabolic
correlation study after treatment.
Br J Psychiatry 1995;166:244-50.
17 Goldberg TE, WeinbergerDR.
The effects of clozapine on neurocognition: an overview.
J Clin Psychiatry 1994;55:88-90.
18 Dencker SJ, Liberman RP.
From compliance to collaboration in the treatment of schizophrenia.
Int Clin Psychopharmacol 1995;9:75-8.
19 Kemp R, Kirov G, Everitt B, Hayward P, David A.
Randomized controlled trial of compliance therapy.
Br J Psychiatry 1998;172:413-9.
20 Penn DL, Mueser KT, Spandling W, Hape DA, Reed D.
Information processing and social competence in chronic schizophrenia.
Schizophr Bull 1996;21:269-81.
21 Braff DL.
Information processing and attention dysfunction in schizophrenia.
Schizophr Bull 1993;19:233-59.